Companies › ChromaDex
1 active drug program in 1 registered trial: 1 Phase 1; Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Niagen® Plus Nicotinamide riboside (NR) precursor; boosts NAD+ biosynthesis via salvage pathway | NAPRT1 | Phase 1 | Healthy Volunteer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07251608 | Niagen® Plus | Phase 1 | Healthy Volunteer | Other | Feb 2026 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.